Sold as Ceretec, Drax Exametazime. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Technetium Tc-99m Exametazime Kit (sold as Ceretec, Drax Exametazime), first approved Dec 30, 1988, with 1 new use approved and 0 published complete response letters.
| Dec 30, 1988 | CeretecNDA 19829 · New molecular entity | Ge Healthcare | 17 | Marketed |
| Aug 17, 2017 | Drax ExametazimeNDA 208870 · New formulation or manufacturer | Jubilant | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA